- EXACT Sciences (NASDAQ:EXAS +13.3%) Q4 results: Revenues: $35.2M (+144.4%); Operating Loss: ($37.7M) (+6.7%); Net Loss: ($37.2M) (+7.0%); Loss Per Share: ($0.34) (+17.1%).
- 2016 results: Revenues: $99.4M (+152.3%); Operating Loss: ($169M) (-6.2%); Net Loss: ($167.2M) (-6.0%); Loss Per Share: ($1.63) (+4.7%); Quick Assets: $311.1M (+1.4%).
- 2017 Guidance: Revenues: $170M - 180M; Cologuard test volume: at least 415,000.
- Q1 Guidance: Cologuard test volume:88,000.
EXACT Sciences revenues up 144% in Q4; updates guidance
Recommended For You
About EXAS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EXAS | - | - |
Exact Sciences Corporation |